Puma Biotechnology Inc. (PBYI)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported the grant of one inducement award to a new hire in Sept. 2025, as required by Nasdaq Listing Rule 5635(c)(4).

Puma Biotech (PBYI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.

Puma (PBYI) Q2 Revenue Rises 11%

Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan H. Auerbach - Founder, Chairman, President, CEO & Secretary Heather Blaber ...

Puma Biotech (PBYI) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to a loss of $0.05 per share a year ago.

LOS ANGELES--(BUSINESS WIRE)--On August 7, 2025, Puma Biotechnology will host a conference call/webcast to review its financial results for the second quarter of 2025.

INTU, NTGR, PBYI and DASH make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.